A novel angiogenesis inhibitor, sunitinib malate, in encapsulating peritoneal sclerosis
Articles > Article · 2011
Authors: Devrim BOZKURT, Banu SARSIK KUMBARACI, Ender HUR, Muhittin ERTILAV, Burcak KARACA, Ozge TİMUR, Selahattin BIÇAK, Selahattin Fehmi AKÇİÇEK, Soner DUMAN
JOURNAL OF NEPHROLOGY, Journal Indexed in SCI Expanded, International, 2011, vol 24, pp 359-365
DOI: 10.5301/jn.2010.6257
Summary
Introduction: Encapsulated peritoneal sclerosis (EPS) is characterized by neoangiogenesis and fibrosis. Increased inflammation is the leading cause of EPS. In turn, neoangiogenesis is both a consequence of and contributor to inflammation. The effects of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, have been postulated in various antiangiogenesis, antiinflammatory and antifibrotic processes both in vitro and in vivo. This novel angiogenesis inhibitor, Sutent (sunitinib malate), was investigated in our rat EPS model.